Peter Harwin serves as Director of the Company. Peter Harwin is currently managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as strategic advisor to Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin also serves on the board of directors of Cogent Biosciences, Inc. He received his Bachelor of Business Administration degree from Emory University.
Peter Harwin is 34, he's been the Director of Miragen Therapeutics Inc since 2020. There are 8 older and no younger executives at Miragen Therapeutics Inc. The oldest executive at Miragen Therapeutics Inc is Arlene Morris, 68, who is the Independent Director.
Peter's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 2500, , PHILADELPHIA, PA, 19103.
Over the last 8 years, insiders at Miragen Therapeutics Inc have traded over $636,110 worth of Miragen Therapeutics Inc stock and bought 1,041,411 units worth $5,368,137 . The most active insiders traders include Bennett S Lebow, Bruce Booth, and Paul D Rubin. On average, Miragen Therapeutics Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,345,685. The most recent stock trade was executed by Global Master Fund Lp Logos on 9 November 2020, trading 476,667 units of MGEN stock currently worth $2,268,935.
Miragen Therapeutics Inc executives and other stock owners filed with the SEC include: